NEW YORK, March 13, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of DaVita Inc. securities (NYSE:DVA) from August 5, 2015 through October 21, 2016, inclusive (the “Class Period”) of the important April 3, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for DaVita investors under the federal securities laws.
To join the DaVita class action, go to http://rosenlegal.com/cases-1026.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) DaVita was using American Kidney Fund as a vehicle to facilitate these improper practices; (3) as such, DaVita’s revenues and profits were illegally obtained; (4) in turn, DaVita lacked effective internal controls over financial reporting; and (5) as a result, Defendants’ statements about DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1026.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 



